摘要
目的 研究阿立哌唑与利培酮治疗精神分裂症(schizophrenia,SCH)的临床有效性。方法 便利选取2019年9月—2021年9月南京市佑安医院收治的SCH患者78例为研究对象,根据全盲掷币方式将其分为比对组和研究组,每组39例。比对组接受常规单一利培酮给药治疗,研究组接受阿立哌唑与利培酮联合治疗。对比两组患者的不良反应发生率及治疗优良率。结果 研究组患者的不良反应发生率(5.13%)显著低于比对组(25.64%),差异有统计学意义(χ^(2)=6.303,P=0.012);研究组患者的治疗效果优良率(92.31%)显著高于比对组(71.79%),差异有统计学意义(χ^(2)=5.571,P=0.018)。结论 阿立哌唑与利培酮联合治疗SCH能有效保障安全用药,降低药物治疗期间的不良反应发生率,从而提升整体疗效,更利于长期治疗给药。
Objective To investigate the clinical effectiveness of aripiprazole and risperidone in schizophrenia.Meth⁃ods 78 cases of SCH patients admitted to Nanjing You´an Hospital from September 2019 to September 2021 were randomly selected as subjects.They were divided into control group and study group according to the blind coin toss method,with 39 cases in each group.The control group received conventional single risperidone treatment,while the study group received aripiprazole and risperidone combined treatment.The incidence of adverse reaction and the excellent and good rate of the curative effect of the two groups were compared.Results The adverse reaction rate of the study group(5.13%)was significantly lower than that of the control group(25.64%),the difference was statistically significant(χ^(2)=6.303,P=0.012).The rate of excellent and good efficacy in the study group(92.31%)was significantly higher than that in the control group(71.79%),and the difference was statistically significant(χ^(2)=5.571,P=0.018).Conclusion The combination of aripiprazole and risperidone in the treatment of SCH can effectively guarantee the safety of drug use and reduce the incidence of adverse reaction during drug treatment,so as to improve the overall efficacy and facilitate the long-term treatment.
作者
黄慧
HUANG Hui(Department of Psychiatry II,Nanjing You´an Hospital,Nanjing,Jiangsu Province,211123 China)
出处
《中外医疗》
2022年第35期141-145,共5页
China & Foreign Medical Treatment
关键词
阿立哌唑
利培酮
精神分裂症
不良反应率
疗效优良率
有效性
Aripiprazole
Risperidone
Schizophrenia
Adverse reaction rate
Good and good rate of curative effect
Validity
